Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan.

Medical devices provide an ecological niche for microbes to flourish as a biofilm community, protected from antimicrobials and host defenses. Biofilms formed by Candida albicans, the most common fungal pathogen, survive exposure to extraordinarily high drug concentrations. Here, we show that beta-glucan synthase Fks1p produces glucan, which is deposited in the biofilm matrix. The extracellular glucan is required for biofilm resistance and acts by sequestering antifungals, rendering cells resistant to their action. These findings provide the genetic basis for how biofilm matrix production governs drug resistance by impeding drug diffusion and also identify a useful biofilm drug target.

[1]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. Perlin,et al.  Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints , 2008, Antimicrobial Agents and Chemotherapy.

[3]  A. Mitchell,et al.  Complementary Adhesin Function in C. albicans Biofilm Formation , 2008, Current Biology.

[4]  D. Andes,et al.  Beta -1,3 glucan as a test for central venous catheter biofilm infection. , 2007, The Journal of infectious diseases.

[5]  D. Andes,et al.  Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance , 2006, Antimicrobial Agents and Chemotherapy.

[6]  L. J. Douglas,et al.  Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. , 2006, Journal of medical microbiology.

[7]  D. Andes,et al.  Development and Characterization of an In Vivo Central Venous Catheter Candida albicans Biofilm Model , 2004, Infection and Immunity.

[8]  J. Wendland,et al.  New modules for PCR‐based gene targeting in Candida albicans: rapid and efficient gene targeting using 100 bp of flanking homology region , 2003, Yeast.

[9]  H. Bussey,et al.  Large‐scale essential gene identification in Candida albicans and applications to antifungal drug discovery , 2003, Molecular microbiology.

[10]  M. Ghannoum,et al.  Mechanism of Fluconazole Resistance in Candida albicans Biofilms: Phase-Specific Role of Efflux Pumps and Membrane Sterols , 2003, Infection and Immunity.

[11]  B. Wickes,et al.  Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. , 2002, The Journal of antimicrobial chemotherapy.

[12]  A. Mitchell,et al.  RIM101-Dependent and -Independent Pathways Govern pH Responses in Candida albicans , 2000, Molecular and Cellular Biology.

[13]  H. Tabuchi,et al.  Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in beta-1,3-glucan synthesis , 1997, Journal of bacteriology.

[14]  K. Kuchler,et al.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters , 1995, Antimicrobial agents and chemotherapy.

[15]  D. Andes,et al.  Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. , 2007, Antimicrobial agents and chemotherapy.

[16]  D. Andes.  Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. , 2005, Methods in molecular medicine.